Mainz Biomed B.V. (MYNZ) AI Stock Analysis

• Market Cap: $8.61M
• Dividend Yield: N/A
• Average Volume (3M): 350.23K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.27
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 19
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -2.65
• Shares Outstanding: 5,412,853
• 10 Day Avg. Volume: 923,862
• 30 Day Avg. Volume: 350,228
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.69
• Price to Sales (P/S): 4.68
• P/FCF Ratio: -0.24
• Enterprise Value/Market Cap: 0.65
• Enterprise Value/Revenue: 6.28
• Enterprise Value/Gross Profit: 9.77
• Enterprise Value/Ebitda: -0.29
• 1Y Price Target: $14.00
• Price Target Upside: 780.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 47 Neutral
• Price Target: $1.50 ▼(-5.66% Downside)

The overall stock score of 47 reflects significant financial challenges faced by Mainz Biomed B.V., including negative profitability and high leverage. Technical analysis indicates a neutral to slightly bearish trend, while the lack of valuation metrics underscores the company's financial difficulties. The absence of earnings call data and corporate events further limits positive influences on the score.

Positive Factors

Product Innovation

The company's emphasis on advanced DNA analysis for cancer detection positions it as a leader in innovative diagnostic solutions, potentially driving long-term growth.

Strategic Partnerships

Collaborations with key industry players enhance distribution and adoption of diagnostic tests, supporting sustained revenue growth and market presence.

Equity Improvement

Recent improvements in equity suggest better financial health, providing a foundation for future investments and operational stability.

Negative Factors

Negative Profitability

Persistent unprofitability and negative margins threaten long-term viability, necessitating strategic shifts to achieve financial sustainability.

High Leverage

Increased leverage limits financial flexibility and heightens risk, potentially impacting the company's ability to invest in growth opportunities.

Negative Cash Flow

Consistently negative operating cash flow indicates challenges in covering operational costs, which could hinder long-term financial health.

Mainz Biomed B.V. Business Overview & Revenue Model

Company Description

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.

How the Company Makes Money

Mainz Biomed generates revenue primarily through the commercialization of its diagnostic tests, which are sold to healthcare providers, hospitals, and laboratories. The company may also engage in partnerships with pharmaceutical companies and research institutions, providing additional revenue streams through collaborative research and development projects. Furthermore, Mainz Biomed may benefit from licensing agreements for its proprietary technologies, enabling it to earn royalties from other entities that utilize its innovations in their own offerings. Additionally, government grants and funding for cancer research initiatives could contribute to the company's earnings, although specific partnership details and revenue figures are not disclosed.

Mainz Biomed B.V. Financial Statement Overview

Summary

Mainz Biomed B.V. is facing significant financial challenges, including negative profitability and high leverage. The company shows some improvements in equity and free cash flows, but sustained negative margins and reliance on financing pose risks. A strategic focus on revenue growth and cost management is crucial for future stability.

Income Statement

Mainz Biomed B.V. has shown fluctuating revenues with recent stagnation, failing to surpass the 2020 revenue levels. Despite some improvement in gross profit margins, the company continues to incur substantial EBIT and net losses, indicating persistent profitability challenges. Net profit margin remains deeply negative, emphasizing ongoing financial hurdles.

Balance Sheet

The company exhibits high leverage with a rising debt-to-equity ratio, indicating potential financial risk. Stockholders' equity has improved recently, but overall equity is still relatively low compared to total assets, suggesting limited financial stability. Return on Equity remains negative, reflecting unprofitability.

Cash Flow

Operating cash flow has been consistently negative, although free cash flow has shown some improvement. Financing activities have been a major source of cash, highlighting reliance on external funding. The operating cash flow to net income ratio is concerning, as cash flows are not covering net losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	893.99K	895.48K	529.88K	577.35K	493.56K
Gross Profit	574.88K	509.66K	182.15K	177.62K	123.08K
EBITDA	-19.56M	-25.01M	-25.72M	-11.28M	-257.64K
Net Income	-21.65M	-26.30M	-26.45M	-11.69M	-586.89K
Balance Sheet
Total Assets	13.24M	15.41M	20.24M	10.04M	673.27K
Cash, Cash Equivalents and Short-Term Investments	6.24M	7.07M	17.14M	8.73M	122.57K
Total Debt	3.27M	7.42M	3.23M	2.58M	2.98M
Total Liabilities	7.19M	12.16M	6.14M	3.68M	3.41M
Stockholders Equity	6.05M	3.25M	14.10M	6.36M	-2.74M
Cash Flow
Free Cash Flow	-17.34M	-23.84M	-15.43M	-3.24M	-478.42K
Operating Cash Flow	-17.09M	-21.94M	-14.77M	-3.22M	-468.74K
Investing Cash Flow	-198.82K	-1.90M	-658.48K	1.20M	-9.69K
Financing Cash Flow	16.60M	14.23M	23.94M	10.61M	396.68K

Mainz Biomed B.V. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.59
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MYNZ, the sentiment is Neutral. The current price of 1.59 is above the 20-day moving average (MA) of 1.56, below the 50-day MA of 1.62, and below the 200-day MA of 2.92, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 51.19 is Neutral, neither overbought nor oversold. The STOCH value of 64.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MYNZ.

Mainz Biomed B.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MYNZ	47 Neutral	$8.61M	―	―	―	―	―
ISPC	39 Underperform	$6.87M	-0.09	-303.74%	―	-43.77%	55.78%
INBS	38 Underperform	$9.26M	―	-186.64%	―	-1.90%	87.72%
NDRA	34 Underperform	$5.83M	-0.01	-167.48%	―	―	77.66%
CHEK	26 Underperform	$11.37M	―	―	―	―	―

Mainz Biomed B.V. Corporate Events

Mainz Biomed Enters $10 Million Equity Distribution Agreement with Maxim Group

On October 3, 2025, Mainz Biomed B.V. entered into an Equity Distribution Agreement with Maxim Group LLC to potentially sell up to $10 million of its ordinary shares. This agreement allows Mainz Biomed to raise capital through ‘at-the-market’ offerings, enhancing its financial flexibility and potentially strengthening its market position. The sales will be conducted through Nasdaq or other U.S. trading markets, with Maxim Group acting as the sales agent. This strategic move could impact Mainz Biomed’s operations by providing additional funds for its ongoing projects and initiatives.

Mainz Biomed Reports Financial Results for First Half of 2025

On September 26, 2025, Mainz Biomed N.V. released its Management’s Discussion and Analysis of Financial Condition and Results of Operations, along with its unaudited financial statements for the first half of 2025. The company reported a significant decrease in revenue by 45% compared to the same period in 2024, primarily due to strategic decisions to cease direct-to-consumer sales and sell its European Oncology Lab business. Despite a reduction in total revenue, Mainz Biomed managed to improve its gross margin from 61% to 66% through cost efficiencies and increased sales to lab partners. The company also highlighted its restructuring efforts in 2024, which included a reduction in operating costs and personnel, contributing to a decrease in overall expenses.

Mainz Biomed Secures $3 Million Through Securities Purchase Agreement

Mainz Biomed N.V., a company involved in the biotechnology sector, has entered into a securities purchase agreement with an institutional investor on August 4, 2025. This agreement involved the sale of 2,222,222 pre-funded units, each consisting of one pre-funded warrant and one and one-half ordinary warrants, expected to generate approximately $3 million in gross proceeds. The offering closed on August 5, 2025, and included a placement agency agreement with Maxim Group, LLC, which acted as the exclusive placement agent.